A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis

Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J

Record Status
This is a systematic review that meets the criteria for inclusion on DARE.

Bibliographic details

PubMedID
15929857

Original Paper URL
http://www.hta.ac.uk/execsumm/summ922.htm

Indexing Status
Subject indexing assigned by NLM

MeSH
Age Factors; Aged; Alendronate /economics /therapeutic use; Bone Density /drug effects; Bone Density Conservation Agents /economics /therapeutic use; Cost-Benefit Analysis; Etidronic Acid /analogs & derivatives /economics /therapeutic use; Evidence-Based Medicine; Female; Fractures, Bone /etiology /prevention & control; Humans; Middle Aged; Osteoporosis, Postmenopausal /complications /drug therapy /economics; Quality-Adjusted Life Years; Raloxifene Hydrochloride /economics /therapeutic use; Randomized Controlled Trials as Topic; Risedronate Sodium; Teriparatide /economics /therapeutic use

AccessionNumber
12005008389

Date bibliographic record published
15/12/2005